Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POWER 2: Dose Response of TMC114/RTV in Experienced HIV-1 Patients
NCT00071097Phase 2Completed
- Sponsor
- Tibotec
- Start
- Oct 2003
- Primary completion
- Feb 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of darunavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Tibotec. Started Oct 2003; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00071097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071097.